Novo Nordisk A/S $NVO Shares Acquired by Mengis Capital Management Inc.

Mengis Capital Management Inc. grew its holdings in Novo Nordisk A/S (NYSE:NVO) by 303.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 66,694 shares of the company’s stock after acquiring an additional 50,154 shares during the quarter. Mengis Capital Management Inc.’s holdings in Novo Nordisk A/S were worth $3,393,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in NVO. Franklin Resources Inc. boosted its holdings in Novo Nordisk A/S by 4,190.8% in the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after purchasing an additional 13,658,867 shares in the last quarter. Capital International Investors raised its holdings in Novo Nordisk A/S by 52.4% during the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after purchasing an additional 6,092,192 shares in the last quarter. Boston Partners acquired a new stake in Novo Nordisk A/S during the third quarter worth approximately $310,199,000. Price T Rowe Associates Inc. MD lifted its position in shares of Novo Nordisk A/S by 99.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock worth $492,940,000 after buying an additional 4,836,285 shares during the last quarter. Finally, Voloridge Investment Management LLC boosted its holdings in shares of Novo Nordisk A/S by 851.6% in the 4th quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock valued at $244,594,000 after buying an additional 4,302,126 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 0.0%

Shares of Novo Nordisk A/S stock opened at $43.20 on Friday. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $74.38. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The company has a market capitalization of $192.89 billion, a P/E ratio of 10.14, a PEG ratio of 3.86 and a beta of 0.78. The company’s fifty day moving average is $42.92 and its two-hundred day moving average is $45.85.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The business had revenue of $10.85 billion during the quarter. Analysts forecast that Novo Nordisk A/S will post 3.45 earnings per share for the current year.

Analyst Ratings Changes

NVO has been the topic of several research analyst reports. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. TD Cowen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price objective for the company. in a research note on Tuesday, March 10th. Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, April 22nd. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Five analysts have rated the stock with a Buy rating, seventeen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.